TABLE 1.
Isolate | MIC (μg/ml)a |
||||
---|---|---|---|---|---|
Ampicillin | Ceftazidime | Levofloxacin | Minocycline | Polymyxin B | |
1775 | 2 | 12 | 0.125 | 0.125 | 0.064 |
1776 | 2 | 12 | 0.125 | 0.125 | 0.5 |
1777 | 2 | 8 | 0.125 | 0.125 | 4 |
1788 | 16 | 64 | >32 | 8 | 0.75 |
1789 | 12 | 48 | >32 | 12 | 1 |
1790 | 16 | 96 | 8 | 4 | 0.5 |
1791 | 24 | 128 | 8 | 1.5 | 0.75 |
1792 | 64 | 64 | 8 | 2 | 0.75 |
1793 | 32 | 64 | 12 | 2 | 0.5 |
1794 | 32 | 96 | 6 | 1.5 | 0.64 |
1795 | 14 | 96 | 4 | 1.5 | 0.125 |
1796 | 128 | 96 | 4 | 2 | 0.125 |
1797 | 256 | 128 | 4 | 2 | 0.38 |
The antibiotic class, target, dose range tested, and susceptibility breakpoints for the tested drugs were as follows: ampicillin, β-lactam, cell wall, 0.016 to 256 μg/ml, susceptibility at ≤8 μg/ml and resistance at ≥32 μg/ml; ceftazidime, β-lactam, cell wall, 0.016 to 256 μg/ml, susceptibility at ≤16 μg/ml and resistance at ≥64 μg/ml; levofloxacin, fluoroquinolone, topoisomerases, 0.002 to 32 μg/ml, susceptibility at ≤2 μg/ml and resistance at ≥8 μg/ml; minocycline, tetracycline, protein synthesis, 0.016 to 256 μg/ml, susceptibility at ≤4 μg/ml and resistance at ≥16 μg/ml; polymyxin B, polypeptide, outer membrane, 0.064 to 1,024 μg/ml, susceptibility at ≤2 μg/ml and resistance at ≥8 μg/ml. Bold numbers indicate resistance.